GO
Loading...

Enter multiple symbols separated by commas

Abbott Laboratories

More

  • CVS paying $10.4B in cash for drug distributor Omnicare Thursday, 21 May 2015 | 7:18 AM ET

    CVS Health will pay more than $10 billion for pharmaceutical distributor Omnicare in a deal primed to feed its fast-growing specialty drug business and tap a lucrative and growing market: care for the elderly. Omnicare's long-term care business operates in 47 states and the District of Columbia. Cincinnati- based Omnicare's core business involves...

  • *Tie-up with Montreal scientists on heart disease genes. LONDON, May 13- AstraZeneca is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease. To redress the balance, AstraZeneca said on Wednesday it had signed two deals, one with Abbott Laboratories for a diagnostic test...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co and believes it can complete the deal by year end. Mylan, on a conference call with analysts, said it is legally committed to take its offer directly to Perrigo shareholders under Irish takeover...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co.. "We remain steadfast in our legally binding commitment to acquire Perrigo and have taken numerous concrete steps to lay out a clear and certain path towards completion," Mylan Chief Executive...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was "steadfast" in its commitment to acquire Ireland- based Perrigo Co.. Perrigo last week rejected a sweetened $34 billion offer from Mylan. At the same time, Mylan is attempting to fend...

  • April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.

  • April 22- Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million, or 14 cents per share, a year earlier.

  • April 22- Abbott Laboratories' net earnings from continuing operations more than doubled in the first quarter, with strong performance in its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million,...

  • Earnings next test for stocks after market wipeout Monday, 20 Apr 2015 | 5:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Earnings next test for stocks after market wipeout Friday, 17 Apr 2015 | 4:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • MUMBAI, April 15- India may go to the World Trade Organisation if the European Union does not reconsider a decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd, the firm's CEO said. The European Medicines Agency suspension became effective in January, a month after France, Germany, Belgium...

  • MUMBAI, April 15- India may go to the World Trade Organization if the European Union does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd, the firm's CEO said. The European Medicines Agency suspension became effective in January, a month after France, Germany, Belgium...

  • Your first trade for Thursday Wednesday, 8 Apr 2015 | 6:14 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Cramer Remix: It's time to buy these oil stocks Wednesday, 1 Apr 2015 | 7:00 PM ET
    Jim Cramer on the set of Mad Money

    The pain may finally be coming to an end for these names, says “Mad Money” host Jim Cramer.

  • Cramer: Watch out! Market's No.1 enemy right now Wednesday, 1 Apr 2015 | 6:12 PM ET
    GoDaddy CEO Blake Irving visits on the floor of the New York Stock Exchange as the website hosting service makes its initial public offering (IPO) on April 1, 2015 in New York.

    Jim Cramer is concerned with the amount of flooding in the market right now, and warns investors to watch out for these signs of a sinking ship.

  • Early movers: SHLD, WMT, GDDY, AAPL & more Wednesday, 1 Apr 2015 | 7:47 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • No bans on NZ dairy products after poison threat -govt Thursday, 12 Mar 2015 | 2:41 AM ET

    Countries including China, the biggest buyer of New Zealand dairy products, were not closing the door on shipments, a top official from the ministry told Reuters, as police track down the sender of letters to dairy giant Fonterra and the national farmers' group which were accompanied by infant formula laced with the pesticide 1080.. Following the announcement...

  • Four trades to go before the closing bell Wednesday, 11 Mar 2015 | 1:29 PM ET

    The "Halftime Report" traders give their final trades of the show.

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...